{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:55:23Z","timestamp":1789811723987,"version":"4.0.1"},"reference-count":45,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,11,21]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.2967\/jnumed.125.270175","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:16:21Z","timestamp":1767111381000},"page":"429-437","source":"Crossref","is-referenced-by-count":3,"title":["Influence of Subcellular Localization on the Cytotoxicity of Targeted \u03b1-Therapy"],"prefix":"10.2967","volume":"67","author":[{"given":"Hwan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarbhanu","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Martorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Sang Uk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Paden","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiaoju S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Mankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pryma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Sellmyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2026030205300695000_67.3.429.1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: a review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol."},{"key":"2026030205300695000_67.3.429.2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2026030205300695000_67.3.429.3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/pharmaceutics13060906","article-title":"Overview of the most promising radionuclides for targeted alpha therapy: the \u201chopeful eight","volume":"13","author":"Eychenne","year":"2021","journal-title":"Pharmaceutics."},{"key":"2026030205300695000_67.3.429.4","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0207"},{"key":"2026030205300695000_67.3.429.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.10.007"},{"key":"2026030205300695000_67.3.429.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00741-y"},{"key":"2026030205300695000_67.3.429.7","doi-asserted-by":"publisher","DOI":"10.1038\/srep37274"},{"key":"2026030205300695000_67.3.429.8","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1931"},{"key":"2026030205300695000_67.3.429.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129551"},{"key":"2026030205300695000_67.3.429.10","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3235"},{"key":"2026030205300695000_67.3.429.11","unstructured":"Sharma . Fluorescent derivatives of trimethoprim for in vivo optical imaging of eDHFR-expressing cells. Unpublished results."},{"key":"2026030205300695000_67.3.429.12","unstructured":"Sharma . Radiopharmaceutical therapy with radioiodinated trimethoprim ([131I]I-TMP) targeting E. coli dihydrofolate reductase. Unpublished results."},{"key":"2026030205300695000_67.3.429.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00604.x"},{"key":"2026030205300695000_67.3.429.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113230"},{"key":"2026030205300695000_67.3.429.15","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.3390\/molecules26133936","article-title":"Studies on the Structure and properties of membrane phospholipase A1 inclusion bodies formed at low growth temperatures using GFP fusion strategy","volume":"26","author":"Bakholdina","year":"2021","journal-title":"Molecules."},{"key":"2026030205300695000_67.3.429.16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0837"},{"key":"2026030205300695000_67.3.429.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233965"},{"key":"2026030205300695000_67.3.429.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267238"},{"key":"2026030205300695000_67.3.429.19","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s42003-022-04209-8","article-title":"Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma","volume":"5","author":"Makvandi","year":"2022","journal-title":"Commun Biol."},{"key":"2026030205300695000_67.3.429.20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00300234"},{"key":"2026030205300695000_67.3.429.21","first-page":"319","article-title":"Body condition scoring: a rapid and accurate method for assessing health status in mice","volume":"49","author":"Ullman-Culler\u00e9","year":"1999","journal-title":"Lab Anim Sci."},{"key":"2026030205300695000_67.3.429.22","first-page":"187","article-title":"Stabilization of dihydrofolate reductase by inhibitors in\u00a0vivo and in\u00a0vitro","volume":"186","author":"Hillcoat","year":"1971","journal-title":"Ann N Y Acad Sci."},{"key":"2026030205300695000_67.3.429.23","doi-asserted-by":"crossref","first-page":"112841","DOI":"10.1016\/j.colsurfb.2022.112841","article-title":"Anticancer effect of rationally designed \u03b1-helical amphiphilic peptides","volume":"220","author":"Pan","year":"2022","journal-title":"Colloids Surf B Biointerfaces."},{"key":"2026030205300695000_67.3.429.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1703109114"},{"key":"2026030205300695000_67.3.429.25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/0929867054020963","article-title":"Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A3 adenosine receptors in human tumor cell lines","volume":"12","author":"Baraldi","year":"2005","journal-title":"Curr Med Chem."},{"key":"2026030205300695000_67.3.429.26","doi-asserted-by":"crossref","first-page":"108368","DOI":"10.1016\/j.nucmedbio.2023.108368","article-title":"Preclinical studies of a PARP targeted, Meitner\u2013Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer","volume":"122-123","author":"Hoffman","year":"2023","journal-title":"Nucl Med Biol."},{"key":"2026030205300695000_67.3.429.27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI112106","article-title":"Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate","volume":"76","author":"Curt","year":"1985","journal-title":"J Clin Invest."},{"key":"2026030205300695000_67.3.429.28","first-page":"1516","article-title":"Overcoming the obstacles to clinical evaluation of 211At-labeled radiopharmaceuticals","volume":"42","author":"Wilbur","year":"2001","journal-title":"J Nucl Med."},{"key":"2026030205300695000_67.3.429.29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40658-020-00326-7","article-title":"Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice","volume":"7","author":"Ukon","year":"2020","journal-title":"EJNMMI Phys."},{"key":"2026030205300695000_67.3.429.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.018"},{"key":"2026030205300695000_67.3.429.31","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.21.591"},{"key":"2026030205300695000_67.3.429.32","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-22-0400","article-title":"Preclinical development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma","volume":"28","author":"Batra","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026030205300695000_67.3.429.33","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1021\/acs.jmedchem.4c02188","article-title":"In vivo stability improvement of astatobenzene derivatives by introducing neighboring substituents","volume":"68","author":"Hirata","year":"2025","journal-title":"J Med Chem."},{"key":"2026030205300695000_67.3.429.34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1524\/ract.1989.47.23.87","article-title":"Nuclear recoils from 211At decay","volume":"47","author":"Roessler","year":"1989","journal-title":"Radiochim Acta."},{"key":"2026030205300695000_67.3.429.35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2307\/3577027","article-title":"Tissue and subcellular distribution of bismuth radiotracer in the rat: considerations of cytotoxicity and microdosimetry for bismuth radiopharmaceuticals","volume":"111","author":"Zidenberg-Cherr","year":"1987","journal-title":"Radiat Res."},{"key":"2026030205300695000_67.3.429.36","doi-asserted-by":"publisher","DOI":"10.2174\/1874471010801030177"},{"key":"2026030205300695000_67.3.429.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42133-5"},{"key":"2026030205300695000_67.3.429.38","doi-asserted-by":"publisher","DOI":"10.1667\/RR1359.1"},{"key":"2026030205300695000_67.3.429.39","doi-asserted-by":"publisher","DOI":"10.1667\/RR2472.1"},{"key":"2026030205300695000_67.3.429.40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0859"},{"key":"2026030205300695000_67.3.429.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110634"},{"key":"2026030205300695000_67.3.429.42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077076"},{"key":"2026030205300695000_67.3.429.43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamaoncol.2020.5660","article-title":"Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial","volume":"7","author":"Bidard","year":"2021","journal-title":"JAMA Oncol."},{"key":"2026030205300695000_67.3.429.44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.9.4959"},{"key":"2026030205300695000_67.3.429.45","doi-asserted-by":"publisher","DOI":"10.3109\/02841869609104038"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:31:10Z","timestamp":1772458270000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.2967\/jnumed.125.270175"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270175","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}